Headlands Technologies LLC Acquires New Holdings in Altimmune, Inc. (NASDAQ:ALT)

Headlands Technologies LLC bought a new position in shares of Altimmune, Inc. (NASDAQ:ALT) during the fourth quarter, HoldingsChannel reports. The fund bought 14,054 shares of the company’s stock, valued at approximately $101,000.

Several other institutional investors also recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its position in Altimmune by 2.0% during the 4th quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company’s stock worth $742,000 after buying an additional 2,028 shares during the period. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Altimmune by 12.9% during the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock worth $144,000 after purchasing an additional 2,687 shares during the period. Teacher Retirement System of Texas grew its stake in shares of Altimmune by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company’s stock worth $153,000 after purchasing an additional 3,423 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in Altimmune by 34.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company’s stock valued at $98,000 after purchasing an additional 3,500 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ALT shares. Stifel Nicolaus assumed coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $52,000. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Altimmune Stock Performance

Altimmune stock opened at $4.24 on Monday. Altimmune, Inc. has a 52-week low of $4.00 and a 52-week high of $11.16. The stock’s 50 day moving average price is $6.01 and its two-hundred day moving average price is $6.95. The stock has a market capitalization of $326.54 million, a price-to-earnings ratio of -2.74 and a beta of 0.91.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. On average, equities research analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.